Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Knight-Swift Transportation Holdings Inc. (KNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Knight-Swift Transportation Holdings Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Knight-Swift Transportation Holdings Inc. trades at $63.41 (market cap $10.26B). The key difference: Knight-Swift Transportation Holdings Inc. is far larger — about 3.6× Dyne Therapeutics Inc. Common Stock's market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.27% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Knight-Swift Transportation Holdings Inc. for 6 Days on average.
| DYN | KNX | |
|---|---|---|
Market Cap | $2.86B | $10.26B |
Volume | 3,341,579 | 4,530,077 |
Sector | Health | Industrials |
52-Week High | $26.78 | $82.45 |
52-Week Low | $14.60 | $41.68 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $12.75B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Knight-Swift Transportation (KNX) trades at $63.01, down 2.34% with bearish technical signals. The company reported mixed earnings with Q2 2026 beating estimates but Q4 2025 missing expectations. Revenue trends show modest growth to $7.7B in 2026, though net income margin compression to 0.55% raises concerns. Analyst consensus remains strongly bullish with 64% buy ratings and $85.75 price target, while technical indicators show selling pressure with support at $63.
The stock presents a divergence between strong Wall Street optimism and current technical weakness. Upside potential exists from truckload margin improvements and capacity-driven freight recovery, but risks include margin pressure, CEO stock sales, and broader transportation sector volatility. The upcoming Q3 2026 earnings report on October 21, 2026 will be critical for validating the bullish analyst thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Knight-Swift Transportation Holdings Inc.
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →
